New CRISPR-based blood test detects pancreatic cancer mutations at 100x higher sensitivity.
CECMS combines CbAgo (which eliminates wild-type DNA) with CRISPR-Cas12a (which detects enriched mutant alleles) to achieve 100-fold higher sensitivity than conventional Cas12a biosensors, detecting VAFs as low as 0.01%. In undiluted human serum, it detected KRAS G12D mutations at 0.1% VAF.
New CRISPR-based blood test detects pancreatic cancer mutations at 100x higher sensitivity.
CECMS combines CbAgo (which eliminates wild-type DNA) with CRISPR-Cas12a (which detects enriched mutant alleles) to achieve 100-fold higher sensitivity than conventional Cas12a biosensors, detecting VAFs as low as 0.01%. In undiluted human serum, it detected KRAS G12D mutations at 0.1% VAF.
Key Findings
- 100-fold higher sensitivity than conventional Cas12a biosensors
- Detects VAFs as low as 0.01%
- Successfully detected KRAS G12D at 0.1% VAF in undiluted human serum
- Operates at 37°C in standard lab conditions
Implications
CECMS could enable liquid biopsy detection of pancreatic cancer at earlier, more treatable stages.
Caveats
Proof-of-concept using spiked serum; abstract-only. Not yet validated in actual patient samples.
Source: Analytica chimica acta — 2026-06-15
